Please login to the form below

Not currently logged in
Email:
Password:

Gedeon Richter strengthens its biotechnology business

Gedeon Richter, and Helm, its German partner, have purchased Strathmann Biotec for EUR 22.9m to expand both companies' biotechnology research activities

Hungary-based generics manufacturer, Gedeon Richter, and Helm, its German partner, have purchased German-headquartered Strathmann Biotec for EUR 22.9m to expand both companies biotechnology research activities.

The joint venture will be 70 per cent owned by Gedeon Richter, with Helm holding the remaining 30 per cent. The deal is subjected to regulatory approval.

Strathmann Biotec has a biotechnology plant for bacterial biotechnology, as well as an R&D laboratory and pilot plant capacity. The company employs 81 staff.

Gedeon Richter says that its strategic goal is to establish a strong biopharmaceutical line to expand its worldwide product portfolio by offering products with high added value.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Running
A marathon and a sprint
Customer experience is a long-distance race and with pharma late out of the blocks, companies need to put their foot down if they want to compete...
5 tactics to master Market Access
Is it time to rethink your game plan? To succeed at Market Access, follow these 5 tactics:...
Finding the patient voice
How patients feel and speak about clinical trials...

Infographics